Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risks and benefits of estrogen therapy for a male-to-female transsexual with a prothrombin gene mutation.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - 1 Jan 2000

Laidlaw Elizabeth, Irwig Michael S

Abstract excerpt

OBJECTIVE: We present the case of a male-to-female transsexual person in her 20s requesting hormone therapy in the setting of a history of a deep venous thrombosis and pulmonary embolus and carrying the prothrombin G20210A gene mutation. METHODS: We interviewed the patient and reviewed her medical records. We carefully weighed the risks and benefits of hormone therapy and took into account two important ethical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Cutaneous
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogens

Share to Prothrombin

Share to Risk Assessment

Share to Thrombosis

Share to Tomography, X-Ray Computed

Share to Young Adult

Source

Identifiers

PMID: 23807525
DOI: 10.4158/EP13103.CR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risks and benefits of estrogen therapy for a male-to-female transsexual with a prothrombin gene mutation.PMID 23807525Read ↗

Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening.Semantic proximity Read ↗

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.Semantic proximity Read ↗

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis.Semantic proximity Read ↗

Prothrombotic mutations, family history and the risk of thrombosis in postmenopausal women: implications for hormone replacement therapy.Semantic proximity Read ↗

HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALLY-INSURED WOMEN 50 TO 64 YEARS OF AGESemantic proximity Read ↗

Estrogen therapy and thrombotic risk.Semantic proximity Read ↗

Invited review: Pharmacogenetics of estrogen replacement therapy.Semantic proximity Read ↗

Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy.Semantic proximity Read ↗

The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study.Semantic proximity Read ↗

Exogenous hormones and hereditary angioedema.Semantic proximity Read ↗

Risk factors for venous thromboembolism in pre-and postmenopausal women.Semantic proximity Read ↗

Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.